Acumen Pharmaceuticals, Inc. announced that it has entered into a senior secured term loan agreement of up to $50 million on November 13, 2023. The transaction will include participation from new lender, K2 HealthVentures. The term loan matures on November 1, 2027 and may be extended to November 1, 2028 if the company achieves certain financing milestones.

On the same date, the company has raised $30 million in its first tranche closing from new lender, K2 HealthVentures. The second tranche of up to $20 million will be funded in installments upon the company?s request.